Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

RCT (n= 1,301) found no difference in median progression-free survival with atezolizumab versus placebo in the ITT population (19.5 vs 18.4 months; HR 0.92; 95% CI, 0.79 to 1.07 The interim (immature) overall survival results showed no significant benefit from atezolizumab.

Journal of Clinical Oncology